Pharmacokinetics and efficacy of subcutaneous infliximab 120 mg every 2 weeks: a post hoc comparison with intravenous dosing in a phase 1 study in patients with inflammatory bowel disease.

Read full text Summarise with VIRAT
Authors: Stefan Schreiber, Byong Duk Ye, Hyunseong Yu, D. H. Kim, Young Nam Lee, Shomron Ben-Horin
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: A phase 1 study of CT-P13 demonstrated pharmacokinetic non-inferiority of subcutaneous (SC) infliximab (IFX) to intravenous (IV) IFX in patients with inflammatory bowel disease. This post hoc analysis aimed to evaluate outcomes in the subset of patients who received IFX SC 120 mg every 2 weeks (Q2W) (eventual approved standard dose). Methods: = 45). Intense pharmacokinetic monitoring was used to compare the 2 subsets between W22 and W30. Results: Between W23 and W25, serum IFX concentrations in both subsets were within a similar range, but from W25 through W30, patients in the SC 120 mg Q2W subset exhibited higher serum IFX concentrations than in the IV 5 mg/kg Q8W subset, yielding significantly higher drug exposure. Efficacy and safety outcomes were comparable between subsets throughout. Conclusions: These data support a favorable pharmacokinetic profile of the approved standard dose of IFX SC.

Fields of Study & Subjects

Inflammatory Bowel Disease Biosimilars and Bioanalytical Methods Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
PubMed Central
Volume
8
Issue
1
Pages
otag008–otag008
Publication date
1 January 2026
Language
EN